Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Short Interest Update

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 16,531 shares, a decline of 66.2% from the May 31st total of 48,965 shares. Based on an average daily trading volume, of 10,212 shares, the days-to-cover ratio is presently 1.6 days.

Rocket Pharmaceuticals Trading Down 20.3%

Rocket Pharmaceuticals stock traded down $0.00 during mid-day trading on Friday, hitting $0.01. 17,105 shares of the company traded hands, compared to its average volume of 27,838. The stock has a fifty day moving average price of $0.01 and a 200-day moving average price of $0.02. Rocket Pharmaceuticals has a one year low of $0.00 and a one year high of $0.08.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.